← Back to Search

Genetic Sequencing

Genome Sequencing for Personalized Cancer Therapy

N/A

Recruiting

Led By Janessa J Laskin, MD

Research Sponsored by British Columbia Cancer Agency

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

ECOG PS 0 or 1

Age >/= 18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial will use full genome sequencing to identify cancer "drivers" and corresponding drugs that may inhibit these pathways, in order to match each individual cancer to a biologically relevant targeted therapy.

Who is the study for?

This trial is for adults with cancer who can provide tissue samples, have a life expectancy of at least 6 months, and are fit enough to potentially participate in future clinical trials. They must be willing to share their genomic data and understand it may guide treatment options.Check my eligibility

What is being tested?

The trial uses full genome sequencing on individual cancers to identify 'drivers' of the disease and match them with targeted therapies that could inhibit these pathways. It aims to personalize cancer treatment based on genetic analysis.See study design

What are the potential side effects?

Since this trial involves genome sequencing rather than drug interventions, traditional side effects are not applicable. However, there might be risks associated with biopsy procedures or psychological impact from learning about one's genomic information.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am fully active or restricted in physically strenuous activity but can do light work.

Select...

I am 18 years old or older.

Select...

I can provide a recent biopsy or have suitable stored tissue samples for the study.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Cataloging of cancer genomes

Influence of genomic data on clinical decision-making

Trial Design

1Treatment groups

Experimental Treatment

Group I: Genome SequencingExperimental Treatment1 Intervention

There is only one arm to this study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Genome sequencing

2017

N/A

~10

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

British Columbia Cancer AgencyLead Sponsor

171 Previous Clinical Trials

85,511 Total Patients Enrolled

BC Cancer FoundationOTHER

17 Previous Clinical Trials

3,359 Total Patients Enrolled

Janessa J Laskin, MDPrincipal InvestigatorBritish Columbia Cancer Agency

Media Library

Genome sequencing (Genetic Sequencing) Clinical Trial Eligibility Overview. Trial Name: NCT02155621 — N/A

Cancer Research Study Groups: Genome Sequencing

Cancer Clinical Trial 2023: Genome sequencing Highlights & Side Effects. Trial Name: NCT02155621 — N/A

Genome sequencing (Genetic Sequencing) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02155621 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the participant eligibility for this research restricted to those aged sixty and above?

"This research project is seeking participants between 18 and 85 years old. To date, there are 50 studies for minors and 815 studies involving seniors aged 65 or older."

Answered by AI

How many individuals have enrolled in this experiment?

"Yes, the records found on clinicaltrials.gov confirm that this medical trial is enrolling subjects at present. The study was initially posted online on July 1st 2014 and has since been updated as of January 26th 2021. 5000 participants are sought from one location for this investigation."

Answered by AI

Is there still an opportunity for individuals to enroll in the clinical trial?

"The data hosted on clinicaltrials.gov reveals that this trial is currently seeking participants, with the initial posting made on July 1st 2014 and updated as recently as January 26th 2021."

Answered by AI

Who has been determined to be a suitable candidate for this research endeavor?

"This clinical trial is enlisting 5000 individuals aged between 18 and 85 who possess malignant neoplasms. To be eligible for participation, patients must agree to have their archival specimens used (and possibly depleted) for research purposes; they should also consent to providing a blood sample or other normal DNA specimen for germline genomic study; exhibit an Eastern Cooperative Oncology Group performance status of 0 or 1; exceed the age of majority; expect more than 6 months life expectancy while remaining clinically fit in 3-6 months' time; demonstrate measurable disease by RECIST v1.1 criteria or later version thereof, as well as adequate organ function"

Answered by AI

Recent research and studies

The OncologistJournal

Diagnostic Value of Next-generation Sequencing in an Unusual Sphenoid Tumor

Jamshidi, Farzad, Erin Pleasance, Yvonne Li, Yaoqing Shen, Katayoon Kasaian, Richard Corbett, Peter Eirew, et al.. 2014. “Diagnostic Value of Next-generation Sequencing in an Unusual Sphenoid Tumor”. The Oncologist. Oxford University Press (OUP). doi:10.1634/theoncologist.2013-0390.

Genome BiologyJournal

Evolution of an Adenocarcinoma in Response to Selection by Targeted Kinase Inhibitors

Jones, Steven JM, Janessa Laskin, Yvonne Y Li, Obi L Griffith, Jianghong An, Mikhail Bilenky, Yaron S Butterfield, et al.. 2010. “Evolution of an Adenocarcinoma in Response to Selection by Targeted Kinase Inhibitors”. Genome Biology. Springer Science and Business Media LLC. doi:10.1186/gb-2010-11-8-r82.

Molecular Case StudiesJournal

Lessons Learned from the Application of Whole-genome Analysis to the Treatment of Patients with Advanced Cancers

Laskin, Janessa, Steven Jones, Samuel Aparicio, Stephen Chia, Carolyn Ch'ng, Rebecca Deyell, Peter Eirew, et al.. 2015. “Lessons Learned from the Application of Whole-genome Analysis to the Treatment of Patients with Advanced Cancers”. Molecular Case Studies. Cold Spring Harbor Laboratory. doi:10.1101/mcs.a000570.

Investigational New DrugsJournal